|
Report No. : |
326693 |
|
Report Date : |
11.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
CELLTRION
PHARM INC. |
|
|
|
|
Registered Office : |
82, 2sandan-ro Ochang-eup, Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Korea |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.03.2015 |
|
|
|
|
Date of Incorporation : |
17.11.2000 |
|
|
|
|
Com. Reg. No.: |
214-86-71641 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employee
: |
383 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 97845839 |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated
incredible economic growth and global integration to become a high-tech
industrialized economy. In the 1960s, GDP per capita was comparable with levels
in the poorer countries of Africa and Asia. In 2004, South Korea joined the
trillion-dollar club of world economies, and is currently the world's 12th
largest economy. A system of close government and business ties, including
directed credit and import restrictions, initially made this success possible.
The government promoted the import of raw materials and technology at the
expense of consumer goods, and encouraged savings and investment over
consumption. The Asian financial crisis of 1997-98 exposed longstanding
weaknesses in South Korea's development model, including high debt/equity
ratios and massive short-term foreign borrowing. GDP plunged by 7% in 1998, and
then recovered by 9% in 1999-2000. South Korea adopted numerous economic
reforms following the crisis, including greater openness to foreign investment
and imports. Growth moderated to about 4% annually between 2003 and 2007. South
Korea's export focused economy was hit hard by the 2008 global economic
downturn, but quickly rebounded in subsequent years, reaching over 6% growth in
2010. The US-Korea Free Trade Agreement was ratified by both governments in
2011 and went into effect in March 2012. Between 2012 and 2014, the economy
experienced sluggish growth because of external market slowdowns. The
administration in 2015 is likely to face the challenge of balancing heavy
reliance on exports with developing domestic-oriented sectors, such as
services. The South Korean economy's long-term challenges include a rapidly
aging population, inflexible labor market, dominance of large conglomerates
(chaebols), and the heavy reliance on exports, which comprise about half of
GDP.
|
Source
: CIA |
Basic
|
Company Name |
CELLTRION
PHARM INC. |
|
Registered Address |
82, 2sandan-ro Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do,
Korea (Old Address System : 330, Songdae-ri, Ochang-eup, Cheongwon-gu,
Cheongju-si,Chungcheongbuk-do, Korea) |
|
Building |
|
|
Zip Code |
363-886 |
|
Tel |
+82-2-2216-3611 |
|
Fax |
+82-2-2216-0355 |
|
E-mail |
dsoh@celltrionph.com |
|
Website |
www.celltrionph.com |
|
Trading Address |
17Fl., Kait Tower Bldg., 306, Teheran-ro,
Gangnam-gu, Seoul, Korea (Old Address System : 17Fl., Kait Tower Bldg.,
706-1, Yeoksam 2-dong, Gangnam-gu, Seoul, Korea) |
|
Tel |
+82-2-2216-3611 |
|
Fax |
+82-2-2216-0355 |
|
Other Address-Jincheon Factory |
47-17, Banji-gil, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do, Korea |
|
Tel |
+82-43-533-1611 |
|
Other Address-Ochang Factory |
123, Jusung-ri, Ochang-eup, Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Korea |
|
Tel |
+82-43-217-5545~8 |
|
Type |
Export |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Fever Reducer, Anti Inflammatory, Painkiller |
|
Established (mm/dd/yyyy) |
11/17/2000 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs used for gallbladder disease(51172000) |
|
Sell |
Antifungal drugs(51101800) |
|
Sell |
Antidiabetic agents and hyperglycemic agents(51181500) |
|
Name |
Kim Man-Hoon |
|
Date of Birth |
10/1958 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
9,917,095,500 |
||||||||||||
|
Employees |
383 |
||||||||||||
|
Formation |
Listed Company (KOSDAQ : 068760) as of 02/03/2006 |
||||||||||||
|
Bank Details |
Woori Bank Industrial Bank of Korea Kookmin Bank |
||||||||||||
|
Corporate Registered No. |
110111-2112764 |
||||||||||||
|
Business Registered No. |
214-86-71641 |
||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 45331646 |
||||||||||||
|
Shareholder Position |
|
||||||||||||
|
Company History |
11/17/2000 Incorporated as MBIZ Networks
Global Inc. 05/2001 Designated as a Venture Business 07/20/2007 Changed company name to Cordinus
Inc. 07/03/2009 Changed company name to the
present name 08/2009 Acquired Hanseo Pharm Co., Ltd. 10/2011 Awarded US$ 5 Million Export Top
Prize 05/06/2015 Moved to the presently
registered HQ address from 17Fl., Kait Tower Bldg., 306, Teheran-ro,
Gangnam-gu, Seoul, Korea (Old Address System : 17Fl., Kait Tower Bldg.,
706-1, Yeoksam 2-dong, Gangnam-gu, Seoul, Korea) |
||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
Chairman |
Mr. |
Seo Jung-Jin |
Korean |
1957.10.23 |
- |
|
President & CEO |
Mr. |
Kim Man-Hoon |
Korean |
1958.10. |
- |
|
Director |
Mr. |
Kim Hyung-Ki |
Korean |
1965.05.03 |
- |
|
Director |
Mr. |
Kim Haeng-Ok |
Korean |
1951.12. |
Seoul National University, Korea |
|
Outside Director |
Mr. |
Kim Kyung-Yeob |
Korean |
1956.06. |
University of Maryland, USA |
|
Outside Director |
Mr. |
Lee Kwang-Min |
Korean |
1957.04. |
- |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
(*)03/2015 |
15,686,497,251 |
439,053,994,516 |
1,179,737,967 |
|
(*)2014 |
64,708,353,876 |
412,667,481,171 |
6,269,748,108 |
|
(*)2013 |
50,083,248,020 |
359,987,806,514 |
2,642,628,514 |
|
2012 |
44,707,596,162 |
330,075,783,907 |
3,936,476,527 |
|
2011 |
42,273,146,845 |
214,249,766,559 |
2,401,324,435 |
|
2010 |
40,219,109,203 |
177,830,224,887 |
5,217,361,721 |
(*)Figures are
based on the K-IFRS Accounting System.
|
Authorized Capital(KRW) |
40,000,000,000 |
|
Paid-Up Capital(KRW) |
9,917,095,500 |
|
Total Issued Shares |
19,834,191 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
01/01/2015~03/31/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Total Assets |
439,053,994,516 |
412,667,481,171 |
359,987,806,514 |
|
Current Assets |
163,313,078,886 |
145,086,493,795 |
137,318,114,434 |
|
Cash & Cash Equivalents |
10,616,073,576 |
2,546,271,163 |
10,071,947,222 |
|
Trade Receivables |
38,307,282,690 |
39,362,493,520 |
34,685,000,643 |
|
Other Receivables |
20,093,309,820 |
19,365,589,771 |
5,893,668,688 |
|
Inventories |
75,718,340,181 |
75,925,522,371 |
80,129,309,501 |
|
Other Current Assets |
18,578,072,619 |
7,886,616,970 |
6,538,188,380 |
|
Non-Current Assets |
275,740,915,630 |
267,580,987,376 |
222,669,692,080 |
|
Other Long-Term Receivables |
4,742,701,602 |
5,983,114,035 |
4,300,795,955 |
|
Marketable Financial Instruments |
305,760,032 |
305,760,032 |
1,305,760,032 |
|
Investment_Related Companies |
7,301,905,855 |
7,301,905,855 |
7,301,905,855 |
|
Tangibles |
204,691,283,145 |
195,498,894,396 |
144,860,958,371 |
|
Intangibles |
54,129,309,522 |
53,101,137,879 |
42,112,437,015 |
|
Deferred Income Tax Assets |
4,569,955,474 |
5,390,175,179 |
3,327,834,852 |
|
Other Non-Current Assets |
|
|
19,460,000,000 |
|
Total Liabilities |
221,244,129,533 |
198,848,533,194 |
192,572,318,073 |
|
Current Liabilities |
44,256,813,326 |
113,680,748,689 |
26,254,164,413 |
|
Trade Payables |
1,580,669,846 |
804,062,180 |
826,128,074 |
|
Other Payables |
17,385,326,747 |
28,024,077,494 |
5,555,885,908 |
|
Short-Term Borrowings |
14,635,824,423 |
84,253,322,775 |
19,366,185,948 |
|
Other Current Liabilities |
10,654,992,310 |
599,286,240 |
505,964,483 |
|
Non-Current Liabilities |
176,987,316,207 |
85,167,784,505 |
166,318,153,660 |
|
Long-Term Borrowings |
176,149,423,116 |
84,400,766,146 |
165,570,483,063 |
|
Provisions |
704,701,113 |
698,079,475 |
693,792,951 |
|
Provision for Severance &
Retirement |
133,191,978 |
68,938,884 |
53,877,646 |
|
Capital Stock |
183,125,068,707 |
182,652,853,207 |
140,293,814,081 |
|
Profit Surplus |
23,284,560,489 |
22,577,038,022 |
16,307,289,914 |
|
Others |
11,400,235,787 |
8,589,056,748 |
10,814,384,446 |
|
Total Equity |
217,809,864,983 |
213,818,947,977 |
167,415,488,441 |
|
Liab. & Shareholder’s Equity |
439,053,994,516 |
412,667,481,171 |
359,987,806,514 |
|
Income Statement |
|||
|
Unit : Korean Won |
01/01/2015~03/31/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Sales |
15,686,497,251 |
64,708,353,876 |
50,083,248,020 |
|
Cost of Sold Goods |
5,003,706,227 |
21,920,487,146 |
15,384,857,148 |
|
Gross Profit |
10,682,791,024 |
42,787,866,730 |
34,698,390,872 |
|
Selling & Admin. Expenses |
8,734,310,375 |
33,240,707,400 |
25,799,537,805 |
|
R&D |
138,325,184 |
788,366,935 |
1,441,929,964 |
|
Operating Income |
1,810,155,465 |
8,758,792,395 |
7,456,923,103 |
|
Other Income |
25,498,661 |
520,116,923 |
571,848,031 |
|
Other Expenses |
12,810,691 |
113,784,483 |
754,463,958 |
|
Finance Income |
458,390,921 |
783,011,488 |
1,187,507,812 |
|
Finance Expenses |
848,848,099 |
3,655,222,318 |
4,908,987,773 |
|
Income Before Taxes |
1,432,386,257 |
6,292,914,005 |
3,552,827,215 |
|
Income Taxes Expenses |
252,648,290 |
23,165,897 |
910,198,701 |
|
Net Income |
1,179,737,967 |
6,269,748,108 |
2,642,628,514 |
|
Cash Flows |
|||
|
Unit : Korean Won |
01/01/2015~03/31/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Operating Activities Cash Flows |
-482,796,865 |
18,344,095,288 |
-64,389,036,317 |
|
Cash Flows from Operating |
1,079,661,852 |
18,560,078,239 |
-66,251,315,857 |
|
Interests Received |
145,034,275 |
68,858,328 |
325,408,884 |
|
Dividends Received |
|
|
|
|
Interests Paid |
-1,495,422,098 |
1,036,637,452 |
1,615,293,850 |
|
Income Taxes |
-212,070,894 |
-1,321,478,731 |
-78,423,194 |
|
Cash Flows from Investing |
-16,095,373,273 |
-45,046,207,400 |
-34,251,047,276 |
|
Cash Flows from Financing |
24,668,221,648 |
19,156,237,722 |
105,725,930,677 |
|
Increase/Decrease in Cash |
8,069,802,413 |
-7,525,676,059 |
7,082,508,300 |
|
Cash at the Beginning of Year |
2,546,271,163 |
10,071,947,222 |
2,989,438,922 |
|
Cash at the End of Year |
10,616,073,576 |
2,546,271,163 |
10,071,947,222 |
|
Main Products & Services |
Fever Reducer, Anti Inflammatory, Painkiller |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Suppliers |
|
|
Customers |
|
|
Competitors |
DAEWOONG PHARMA CO., LTD.(134811-0075342) 223-23, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA TEL:+82-31-741-7700~4
FAX:+82-31-749-5535 ILDONG PHARMACEUTICAL CO., LTD(110111-0012776) 60, YANGJAE 1-DONG, SEOCHO-GU, SEOUL, KOREA TEL:+82-2-526-3114
FAX:+82-2-526-3030 DONGWHA PHARM IND CO., LTD.(110111-0043870) 5, SUNHWA-DONG, JUNG-GU, SEOUL, KOREA TEL:+82-2-2021-9300 FAX:+82-2-776-7873 |
|
Affiliates |
CELLTRION INC.(135011-0034038) CELLTRION HEALTHCARE CO.,
LTD.(134111-2007066) CELLTRION GSC CO., LTD.(110111-1995723) NEXOL VENTURE CAPITAL CO.,
LTD.(110111-2402660) XEXOL TELECOM CO., LTD.(110111-1995731) OR CHEM CO., LTD.(135511-0196721) CPU CO., LTD.(131411-0213117) DBI INC.(130111-0006816) CELLTRION EUROPE |
|
Overseas Office |
|
|
Liaison Office |
|
|
Overseas Branch |
|
|
Joint Venture |
|
|
Subsidiary |
CELLTRION PHARMA USA INC 10535 WILSHIRE BLVD. #D-04 LOS ANGELES, CA 90024 (100.0% held by the subject company) CELLTRION CHEMICAL RESEARCH CENTER(134511-0058104) (100.0% held by the subject company) |
|
Corporate Ownership |
CELLTRION INC.(135011-0034038) |
|
Major Shareholders |
CELLTRION INC.(135011-0034038) |
|
Cooperative Enterprise |
-Sales License Granting Agreement with CELLTRION HEALTHCARE CO.,
LTD.(134111-2007066) |
|
Sales/ Unit :Mil KRW |
2014 |
2013 |
2012 |
|
Export |
|
|
|
|
Domestic |
|
|
|
|
Total |
|
|
|
The Subject deals with the companies in USA.
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/ Debtor(s)/
Respondent(s) |
Cause |
Amount (KRW) |
Status |
|
|
Seoul Central District Court |
ROCHE DIAGNOSTICS GMBH |
The Subject Company |
Infringement of Patent Right |
50,000,000 |
1st round is proceeding |
Not Available
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.88 |
|
|
1 |
Rs.98.47 |
|
Euro |
1 |
Rs.72.15 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.